Overview
SPD489 in Adults With Persistent Executive Function Impairments (EFI) and Partial or Full Remission of Recurrent Major Depressive Disorder
Status:
Completed
Completed
Trial end date:
2011-04-18
2011-04-18
Target enrollment:
0
0
Participant gender:
All
All
Summary
To evaluate the efficacy of SPD489 for the treatment of executive function impairments (EFI) when used as an adjunct to stable, standard therapy in the setting of partial or full remission from recurrent Major Depressive Disorder (MDD) as measured by the Global Executive Composite (GEC) T-score of the Behavioral Rating Inventory of Executive Functioning - Adult Version (BRIEF-A).Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
ShireTreatments:
Lisdexamfetamine Dimesylate
Criteria
Inclusion Criteria:- Adults aged 18-55 with a primary diagnosis of nonpsychotic uni-polar depression
Exclusion Criteria:
- Current co-morbid psychiatric disorder